Optimizerx Corp OPRX

DataMeds AI, Inc. (Nasdaq: $MEDS ) reported that Corexa Pharmacy, a division of its wholly owned subsidiary Corexa Health, recorded preliminary, unaudited revenue of more than $1 million for September 2026, up more than 66 percent from July 2026. The increase came with an expanding retail customer base and the launch of Tollo Health pharmaceutical-adjunct products, which Corexa Health distributes under a wholesale distribution arrangement. DataMeds AI, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/datameds-ai-inc-1 Interim Co-CEO Gerald Commissiong believes Corexa Pharmacy is well positioned for future growth with the Helomics acquisition closed, and the pharmacy's physical location is also being upgraded to serve as a flagship model: • The closing of the Helomics Corporation acquisition opens up potential demand for oncology-based medications and nutritional support products, in Commissiong's view • The company is in the process of upgrading the physical location of Corexa Pharmacy to serve as the flagship model for the Health Lives Here initiative with NFL Alumni Health • Commissiong said the upgraded pharmacy will be presented as a model for other pharmacies within Corexa Health's network of over 6,500 independent pharmacies Regarding the September result, Gerald Commissiong, Interim Co-CEO of DataMeds AI, stated: "With the recent launch of Tollo Health‘s proprietary dietary supplements and medical foods combined with strong organic growth from our growing retail customer base, we are beginning to see the growth in both prescriptions filled and adjunct product sales." Read the full release: https://datamedsai.com/datameds-ais-corexa-pharmacy-surpasses-1-million-in-monthly-revenue/ DataMeds AI, Inc. (Nasdaq: MEDS) (formerly Wellgistics Health, Inc.) is a healthcare company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its Health IT platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into Tollo Health, LLC’s Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including the distribution of products developed by Tollo Health. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $OPRX, $HCAT, $PHR, $XLV

DataMeds AI, Inc. (Nasdaq: $MEDS ) Interim Co-CEO Gerald Commissiong will present "What Patients Really Want" at the 2026 National Telehealth and Virtual Care Summit in Las Vegas on Monday, September 28, 2026 at 9:15 a.m. PT, the company announced September 25. The talk covers the growing desire among patients across the country to own their individual health data. DataMeds AI, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/datameds-ai-inc-1 The Health Lives Here mobile app incorporates the company's AI and blockchain platforms, while Corexa Health provides pharmacy services: • Health Lives Here is a campaign and mobile healthcare application that DataMeds AI is advancing together with NFL Alumni Health • The Health Lives Here mobile application incorporates the company's artificial intelligence platform EinsteinRx™ and its blockchain-enabled smart contracts platform PharmacyChain™ • The company's Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including the distribution of products developed by Tollo Health, LLC Regarding a summit that will unite healthcare leaders, clinicians, technology experts and policymakers, Gerald Commissiong, Interim Co-CEO of DataMeds AI, stated: "I look forward to showcasing our team’s work, outlining our vision of how patient ownership of their data will improve patient care while also reducing provider data access frustrations, and interacting with other leading healthcare providers to discuss how to improve healthcare access for those who need it." Read the full release: https://datamedsai.com/datameds-ai-to-present-at-2026-national-telehealth-and-virtual-care-summit/ DataMeds AI, Inc. (Nasdaq: MEDS) (formerly Wellgistics Health, Inc.) is a healthcare company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its Health IT platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including the distribution of products developed by Tollo Health, LLC. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $OPRX $HCAT, $PHR, $XLV

$OPRX $TTD Great news!!

$OPRX The inventory is expected to become available through OpenPath in the fourth quarter of 2026.

OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network $OPRX $TTD https://stocktwits.com/news/equity/markets/optimize-rx-partners-with-the-trade-desk-to-widen-its-healthcare-ad-network/cZMPH7iRB7d

DataMeds AI, Inc. (Nasdaq: $MEDS ) launched its new corporate website, www.DataMedsAI.com, on September 21, 2026, with the redesigned site aligned to marketing initiatives now pending after two recently announced transactions. The launch follows the company's acquisition of Helomics Corporation's artificial intelligence cancer diagnostics lab from Axe Compute and the settlement of outstanding litigation tied to its 2023 acquisition of Wellgistics, LLC. DataMeds AI, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/datameds-ai-inc-1 Both the Helomics closing and the litigation settlement preceded the launch, and Gerald E. Commissiong ties them to the planned Health Lives Here consumer application: • DataMeds acquired Helomics Corporation's artificial intelligence cancer diagnostics lab, a CLIA-certified laboratory, from Axe Compute • The litigation settlement extinguished approximately $19 million in liabilities from the company's balance sheet and retired 364,099 common shares • Interim Co-CEO Gerald E. Commissiong said the Helomics closing and the litigation settlement leave the company ready to launch the Health Lives Here consumer application as it begins telling the DataMeds story to the broader market Regarding the new site, Gerald E. Commissiong, Interim Co-CEO of DataMeds, stated: "Our new corporate website represents the parent company's new branding. We have retooled our marketing efforts to be AI-centric so that we are able to get organic traction online as we begin to draw earned media interest in our story. We intend to soft launch the Health Lives Here app in short order." Read the full release: https://datamedsai.com/datameds-ai-unveils-new-corporate-website/ DataMeds AI, Inc. (Nasdaq: MEDS) (formerly Wellgistics Health, Inc.) is a Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $OPRX, $HCAT, $PHR, $XLV

DataMEDS AI, Inc. (NASDAQ: $MEDS ) has settled litigation tied to the May 2023 Wellgistics, LLC purchase agreement, extinguishing liabilities of approximately $19 million that had been carried on its balance sheet. The Tampa-based Health IT company pairs its EinsteinRx artificial intelligence platform and PharmacyChain smart contracts platform with pharmacy, pharmaceutical-adjacent and telemedicine business units. DataMEDS AI, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/datameds-ai-inc-1 The consideration came in two parts, cash and retired shares, with the full terms in the company's SEC filing: • 364,099 shares of DataMEDS common stock were retired as part of the settlement agreement. • The company paid a total of $450,000 in cash for the settlement. • Additional terms are set out in a Form 8-K filed with the SEC and linked in the release. Regarding the company's focus following the settlement, Gerald E. Commissiong, Interim Co-CEO of DataMEDS, stated: "The Company is pleased to put this outstanding litigation behind it so it can focus on solving healthcare's biggest challenges for our clients through the vertical integration of healthcare delivery, and the compliant tokenization of pharmaceutical supply tracking and patient data." Read the full release: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/datameds-ai-litigation-settlement-extinguishes-19-million-in-liabilit-1223546 DataMeds AI, Inc. (NASDAQ:MEDS) (formerly Wellgistics Health, Inc.) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer. $OPRX, $HCAT, $PHR, $XLV

$ATHR $CVAT $LXEO $OPRX $PBHC The underlying deal is real — it’s in CVAT’s SEC filing — but the “10.8¢ locked in, 270% return” framing leaves out some key details. The offer price isn’t fixed: it’s calculated as Net Price ÷ shares outstanding, and that gets recalculated at a record date 45 business days after the tender offer even opens, so the final per-share number can still move. The deal also isn’t done — EGS needs at least 90% of shares tendered, plus a separate $7M side-deal for Alchemy Beverages has to close too. And this plays out over months, not days, with the offer staying open 60+ business days and another 30+ after final pricing is set. The gap between the 3-6¢ trading price and the 10¢+ deal price isn’t free money sitting on the table — it’s the market pricing in real risk that this doesn’t close cleanly. Legit news, just not the guaranteed windfall it’s being sold as.